Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2016

01-02-2016 | Short Research Report

An evaluation of clinical pharmacist service on a neurology care unit

Authors: Zhan-Miao Yi, Shu-Sen Sun, Xiao-Xiao Li, Ming Lu, Suo-Di Zhai

Published in: International Journal of Clinical Pharmacy | Issue 1/2016

Login to get access

Abstract

Background Medications used to treat neurological diseases may result in adverse effects. Research is needed to demonstrate pharmacist value and their roles in patient care. Objective To categorize the types and severities of the prescribing errors intercepted and to describe clinical activities conducted by neurology ward pharmacists. Method Pharmacists prospectively reviewed medication orders over an 18-month period with inventions documented and categorized. Results A total of 341 prescribing errors in 1183 patients were intercepted. The most common error types were dosing frequency (35.8 %) and medication selection (21.5 %). The top five most detected error medications were those indicated for hyperhomocysteinemia (22.0 %), stress ulcer prophylaxis (12.3 %), poor circulation (10.9 %), hyperglycemia (6.5 %), and infections (5.9 %). Although 67.5 % of the detected errors having the potential causing no harm, 26.4 % of the errors may require intervention, and 6.2 % may increase the length of stay. The number of errors decreased from 19 to 10 per month during the study period. Clinical pharmacists also actively engaged in medication use evaluation, clinical decision support system optimization, and education to patients and providers. Conclusion Presence of clinical pharmacists at the neurology unit may help in early detection of prescribing errors with increased patient safety.
Literature
1.
go back to reference Welty TE. Neurology and neurosurgery clinical pharmacy practice: ignorance, phobia, or progress? Ann Pharmacother. 2006;40(12):2235–7.CrossRefPubMed Welty TE. Neurology and neurosurgery clinical pharmacy practice: ignorance, phobia, or progress? Ann Pharmacother. 2006;40(12):2235–7.CrossRefPubMed
2.
go back to reference Murphy AP, Bentur H, Dolan C, Bugembe T, Gill A, Appleton R. Outpatient anti-epileptic drug prescribing errors in a Children’s Hospital: an audit and literature review. Seizure. 2014;23(9):786–91.CrossRefPubMed Murphy AP, Bentur H, Dolan C, Bugembe T, Gill A, Appleton R. Outpatient anti-epileptic drug prescribing errors in a Children’s Hospital: an audit and literature review. Seizure. 2014;23(9):786–91.CrossRefPubMed
3.
go back to reference Bourne RS, Dorward BJ. Clinical pharmacist interventions on a UK neurosurgical critical care unit: a 2-week service evaluation. Int J Clin Pharm. 2011;33(5):755–8.CrossRefPubMed Bourne RS, Dorward BJ. Clinical pharmacist interventions on a UK neurosurgical critical care unit: a 2-week service evaluation. Int J Clin Pharm. 2011;33(5):755–8.CrossRefPubMed
4.
go back to reference Taegtmeyer AB, Curkovic I, Corti N, Rosen C, Egbring M, Russmann S, et al. Drug-related problems and factors influencing acceptance of clinical pharmacologists’ alerts in a large cohort of neurology inpatients. Swiss Med Wkly. 2012;142:w13615.PubMed Taegtmeyer AB, Curkovic I, Corti N, Rosen C, Egbring M, Russmann S, et al. Drug-related problems and factors influencing acceptance of clinical pharmacologists’ alerts in a large cohort of neurology inpatients. Swiss Med Wkly. 2012;142:w13615.PubMed
6.
go back to reference Van Berkel MA, Hurdle AC, Twilla JD. Phenytoin–rifampin drug interaction in a hypoalbuminemic, renal failure patient: a complex clinical case. Pharmacotherapy. 2013;33(6):e96–100.CrossRefPubMed Van Berkel MA, Hurdle AC, Twilla JD. Phenytoin–rifampin drug interaction in a hypoalbuminemic, renal failure patient: a complex clinical case. Pharmacotherapy. 2013;33(6):e96–100.CrossRefPubMed
7.
go back to reference Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Heart outcomes prevention evaluation 2 investigators homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40(4):1365–72.CrossRefPubMed Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Heart outcomes prevention evaluation 2 investigators homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40(4):1365–72.CrossRefPubMed
8.
go back to reference Yi ZM, Zhai SD, Huang S, Wang TS, Liu F. Off-label prescriptions for adult neurological patients: a pilot survey in China. Int J Clin Pharm. 2012;34(1):81–7.CrossRefPubMed Yi ZM, Zhai SD, Huang S, Wang TS, Liu F. Off-label prescriptions for adult neurological patients: a pilot survey in China. Int J Clin Pharm. 2012;34(1):81–7.CrossRefPubMed
Metadata
Title
An evaluation of clinical pharmacist service on a neurology care unit
Authors
Zhan-Miao Yi
Shu-Sen Sun
Xiao-Xiao Li
Ming Lu
Suo-Di Zhai
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0224-y

Other articles of this Issue 1/2016

International Journal of Clinical Pharmacy 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.